LUA011 / Qilu Pharma - LARVOL DELTA

Preclinical development of LUA011, a novel CDH17/cMET bispecific ADC with enhanced antitumor efficacy and mitigated gastrointestinal toxicity (AACR 2026) - "LUA011 is a novel bispecific ADC targeting both CDH17 and c-Met with favorable physicochemical properties, strong target binding, cellular internalization and potent antitumor activity in preclinical GI cancer models. Its dual targeting activity, along with its optimized payload, conjugation method, and DAR value, contribute to its strong anti-tumor efficacy, improved therapeutic index, and reduced GI toxicities. Further investigation is warranted to advance this promising ADC into clinical development."

ADC • Bispecific • Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17 • MET